EP3795181
MEÐFERÐ VIÐ AMD MEÐ AAV2 AFBREYTINGU MEÐ AFLIBERCEPT
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
16.6.2017EP published:
6.8.2025EP application number:
20196657.9
EP translation filed:
17.10.2025Grant published:
15.11.2025EPO information:
European Patent Register
Max expiry date:
15.6.2037Expiry date:
15.6.2026
Title in English:
TREATMENT OF AMD USING AAV2 VARIANT WITH AFLIBERCEPTLanguage of the patent:
English
Timeline
Today
16.6.2017EP application
6.8.2025EP Publication
17.10.2025Translation submitted
15.11.2025Registration published
15.6.2026Expires
Owner
Name:
Adverum Biotechnologies, Inc.Address:
100 Cardinal Way, Redwood City, CA 94063, US
Inventor
Name:
BLUMENKRANZ, MarkAddress:
California 94063, US
Name:
GASMI, MehdiAddress:
California 94063, US
Agent
Name:
Novagraaf BrevetsAddress:
Bâtiment O2, 2 rue Sarah Bernhardt CS90017, FR
Priority
Number:
201662351234 PDate:
16.6.2016Country:
US
Classification
Categories:
A61K 48/00, A61K 35/761, A61P 27/02, C12N 15/09